Phosphates in medications: Impact on dialysis  patients
.

Phosphates in medications: Impact on dialysis patients
.
Clin Nephrol. 2020 Feb 12;:
Authors: Sawin DA, Ma L, Stennett A, Ofsthun N, Himmele R, Kossmann RJ, Maddux FW
Abstract
Maintaining phosphorus balance in in-center hemodialysis (ICHD) patients is problematic despite recommended dietary restriction, dialysis, and phosphate binder use. Rarely is P content in prescribed medications considered, but this source should raise concern. Data was obtained from the Fresenius Kidney Care (FKC) electronic data warehouse Knowledge Center and MedReview-eRx accessed Surescripts, housing > 80% of US-filled prescriptions. Adult FKC ICHD patients prescribed ≥ 1 medication in the MedReview-eRx database were analyzed (695,759 prescriptions). Information collected included medication dose, dose unit, dose timing, strength, start and stop dates, refills, demographic information, admission history, and modality type. Numbers of patients, prescriptions by individual medication, and drug class were then analyzed. Medications prescribed > 100 times were reported. Median doses/day (number of tablets) were calculated for each medication (open order on randomly selected day). Phosphate content of medications taken in FKC clinics was assessed using routinely used pharmacology references, and potential resulting phosphate and pill burden were also calculated. The top five prescribed drug classes in FKC dialysis patients were calcium-channel block...

Source: Clinical Nephrology - February 11, 2020 Category: Urology & Nephrology Authors: Sawin DA, Ma L, Stennett A, Ofsthun N, Himmele R, Kossmann RJ, Maddux FW Tags: Clin Nephrol Source Type: research